Similar to anti‐TIM‐3‐based immunotherapy, the coadministration of the anti‐TIGIT antibody ociperlimab with anti‐PD‐1 therapy activates NK cell responses and delays tumor growth [358]. This evidence concerns the gene HAVCR2 and neoplasm.